350 rub
Journal №9 for 2014 г.
Article in number:
Estimation of influence of the 4-chlorphenyl-2-hydroxy-4-oxo-2-butenoate thiazolineammonium on hemostasis in rabbits and mice at intragastric introduction
Authors:
A.V. Starkova - Ph.D. (Med.), Senior Lecturer, Department of Physiology and Pathology, Perm State Pharmaceutical Academy. E-mail: allaperm@list.ru
B.Y. Syropyatov - Dr. Sc. (Med.), Professor, Head of the Department of Physiology and Pathology, Perm State Pharmaceutical Academy. E-mail: syropyatov@mail.ru
F.V. Sobin - Ph.D. (Pharm.), Senior Lecturer, Department of Pharmaceutical Technology, Perm State Pharmaceutical Academy
N.A. Pulina - Dr. Sc. (Pharm.), Professor, Head of the Department of Pharmaceutical Technology, Perm State Pharmaceutical Academy
Abstract:
The goal was to study the influence of the 4-chlorophenyl-2-hydroxy-4-oxo-2 - butenoatethiazoline ammonium(FS 169) on blood clotting intragastric introduction of rabbits, the duration of bleeding and on the development of the simulated acute thrombosis of intragastric introduction mice. The findings indicate that the substance FS 169 refers to the toxicity class 3, i.e. it is moderately toxic. Has the effect of intragastric introduction. Operates in the body rabbits and mice. Enough is rapidly absorbed. The most pronounced effect on the collapse of whole blood intragastric introduction celebrated for over 30 minutes after the connection. Substance slows blood clotting. The duration of effect connection FS 169 intragastric introduction persists for 2 hours. Significantly reduces the development of acute thrombosis at intravenous introduction of thrombin. Therefore, this material is promising for further in-depth research.
Pages: 18-21
References

  1. Averkov O.V. Nizkomolekulyarny'e gepariny' v novy'x rekomendacziyax po vedeniyu bol'ny'x ostry'm koronarny'm sindromom bez stojkix pod''emov segmenta ST na E'KG // Klinicheskaya farmakologiya i terapiya. 2008. T. 17. № 1. S. 36-40.
  2. Analizator pokazatelej gemostaza MINILAB 701. Texnicheskoe opisanie i instrukcziya po e'kspluataczii. M.: A/O Junimed. 2002. 36 s.
  3. Baluda V.P., Barkagan Z.S., Gol'dberg E.D. i dr. Laboratorny'e metody' issledovaniya sistemy' gemostaza. Tomsk. 1980. 313 s.
  4. Golovacheva T.V., Skvorczov V.V., Skvorczov K.Ju. Primenenie antikoagulyantov pri serdechno-sosudisty'x zabolevaniyax. Aterotromboz. № 2. 2009. S. 2-19.
  5. Latfulin I.A., Podol'skaya A.A. Primenenie antikoagulyantov pri ostrom koronarnom sindrome // Aktual'ny'e voprosy' klinicheskoj farmakologii. 2009. № 3. S. 71-75.
  6. Nikonov V.V. Kursov S.V. Mexanizm dejstviya antikoagulyantov i perspektivy' klinicheskogo primeneniya rivaroksabana - pervogo e'ffektivnogo ingibitora faktora XA s vozmozhnost'yu e'nteral'nogo vvedeniya // Mediczina neotlozhny'x sostoyanij. 2011. № 3 (34). S. 52-57.
  7. Prozorovskij V.V. Statisticheskaya obrabotka rezul'tatov farmakologicheskix issledovanij. Psixofarmakologiya i biologicheskaya narkologiya. Tom 7 vy'pusk 3-4. Moskva. 2007. S. 2090-2120.
  8. Pulina N.A., Zalesov V.V., Jushkov V.V. i dr. Sintez i biologicheskaya aktivnost' solej geterocziklicheskix aminov i geterilamidov na osnove 4-aril-2,4-dioksobutanovy'x kislot // Voprosy' biologicheskoj, mediczinskoj i farmaczevticheskoj ximii. 2008. № 2. S. 37-40.